NVS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.53
Percentage change -0.52	%

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN REGN VRTX

| Held by: DFIV DFIC DFAI FVD DFAX GCOW AVDE PPH DIHP PID

Scroll to Statements

Index	-	P/E	11.90	EPS (ttm)	8.57	Insider Own	0.00%	Shs Outstand	2.00B	Perf Week	-3.57%
Market Cap	199.54B	Forward P/E	12.42	EPS next Y	8.21	Insider Trans	-	Shs Float	1.96B	Perf Month	-4.51%
Income	17.60B	PEG	1.68	EPS next Q	1.83	Inst Own	6.77%	Short Float	0.24%	Perf Quarter	-12.95%
Sales	48.59B	P/S	4.11	EPS this Y	17.13%	Inst Trans	-0.46%	Short Ratio	4.22	Perf Half Y	-3.17%
Book/sh	21.67	P/B	4.71	EPS next Y	8.36%	ROA	10.88%	Short Interest	4.79M	Perf Year	5.09%
Cash/sh	7.17	P/C	14.23	EPS next 5Y	7.07%	ROE	28.87%	52W Range	92.35 - 120.92	Perf YTD	1.01%
Dividend Est.	3.78 (3.71%)	P/FCF	13.52	EPS past 5Y	5.63%	ROI	25.64%	52W High	-15.65%	Beta	0.56
Dividend TTM	3.74 (3.67%)	Quick Ratio	0.90	Sales past 5Y	0.78%	Gross Margin	73.83%	52W Low	10.44%	ATR (14)	1.34
Dividend Ex-Date	Mar 07, 2024	Current Ratio	1.11	EPS Y/Y TTM	130.88%	Oper. Margin	29.63%	RSI (14)	33.04	Volatility	0.80% 0.85%
Employees	76057	Debt/Eq	0.74	Sales Y/Y TTM	-4.82%	Profit Margin	36.23%	Recom	2.82	Target Price	116.12
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	85.38%	Payout	44.73%	Rel Volume	0.71	Prev Close	102.52
Sales Surprise	0.24%	EPS Surprise	6.27%	Sales Q/Q	8.84%	Earnings	Oct 29 BMO	Avg Volume	1.14M	Price	101.99
SMA20	-1.87%	SMA50	-6.97%	SMA200	-4.32%	Trades		Volume	801,662	Change	-0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform
Sep-14-22	Downgrade	Berenberg	Buy → Hold
May-09-22	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-22	Resumed	Citigroup	Buy

Show Previous Ratings

Today 12:30PM	Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML (GlobeNewswire)
Dec-06-24 01:15AM	New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy (GlobeNewswire)
Dec-04-24 09:45AM	Why Novartis (NVS) is a Top Growth Stock for the Long-Term (Zacks)
07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
04:42AM	Loading…
04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily)
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)
12:40PM	PTC Therapeutics Stock Soars on Novartis Licensing Agreement (Investopedia)
11:29AM	Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% (GuruFocus.com)
07:47AM	Analyst Report: Novartis AG (Morningstar Research)
07:00AM	PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program (PR Newswire)
05:56AM	Novartis wagers billions of dollars on PTC Huntingtons drug (BioPharma Dive)
Dec-01-24 03:45PM	2 Dividend Stocks to Buy and Hold Forever (Motley Fool)
Nov-30-24 07:05PM	Novartis AG (NVS): A Bull Case Theory (Insider Monkey)
04:17PM	Loading…
04:17PM	Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
Nov-27-24 10:25AM	EC approves Novartis Kisqali to treat early breast cancer (Pharmaceutical Technology)
01:15AM	Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence (GlobeNewswire)
Nov-26-24 06:55AM	Novartis to present data from mpre than 65 abstracts as ASH, SABCS (TipRanks)
Nov-25-24 01:15AM	Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS (GlobeNewswire)
Nov-23-24 10:24AM	Are Hedge Funds Banking on Novartis AG (NVS)'s Core Income Growth? (Insider Monkey)
Nov-22-24 06:41AM	Novartis provides updates to mid-term guidance, now sees 6% sales CAGR 2023-2028 (TipRanks)
04:09AM	Novartis acquires Kate Therapeutics to advance gene therapies (Pharmaceutical Technology)
Nov-21-24 10:17AM	Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline (Benzinga)
06:50AM	Novartis Lifts Midterm Sales Guidance Amid U.S. Expansion (The Wall Street Journal)
06:48AM	Novartis wagers more than $1B on gene therapies for the nervous system (BioPharma Dive)
01:00AM	Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth (GlobeNewswire)
Nov-19-24 08:00AM	Novartis ranks first in 2024 Access to Medicine Index (GlobeNewswire)
07:45AM	Novartis strengthens radiopharma leadership with Ratio Therapeutics deal (Pharmaceutical Technology)
06:35AM	Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer (BioPharma Dive)
08:00AM	Loading…
Nov-18-24 08:00AM	Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate (PR Newswire)
12:44AM	Analyst Report: Novartis AG (Morningstar Research)
Nov-15-24 12:40PM	FDA reviews Sanofi and Regenerons Dupixent label expansion for urticaria (Pharmaceutical Technology)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
08:46AM	Ouch: Why a Healthcare Selloff Really Hurts in Europe (The Wall Street Journal)
Nov-14-24 09:35AM	Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS) (Zacks)
Nov-13-24 09:55AM	Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:35AM	Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS) (Zacks)
08:37AM	Q3 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:56AM	Schrodinger announces expanded license agreement with Novartis (TipRanks)
06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive)
03:28AM	Q3 2024 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
02:06AM	Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
12:54AM	Q3 2024 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-12-24 11:06AM	Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details (Benzinga)
Nov-08-24 09:36AM	Analyst Report: Novartis AG (Morningstar Research)
Nov-05-24 09:40AM	Is Novartis (NVS) Stock Undervalued Right Now? (Zacks)
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
Nov-02-24 05:38AM	Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper (Reuters)
Oct-30-24 03:12PM	Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights (Benzinga)
09:40AM	Why Novartis (NVS) is a Top Value Stock for the Long-Term (Zacks)
07:46AM	Novartis Scemblix gains FDA approval for leukaemia (Pharmaceutical Technology)
06:48AM	Novartis Reports Strong Q3 Growth and Raises Guidance (TipRanks)
03:07AM	Novartis AG (NVS) Q3 2024 Earnings Call Highlights: Record Cash Flow and Robust Sales Growth (GuruFocus.com)
Oct-29-24 07:54PM	Analyst Report: Novartis AG (Morningstar Research)
04:11PM	Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker (Investor's Business Daily)
03:03PM	Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile (GlobeNewswire)
02:15PM	Novartis Stock Dives on $800 Million Write-Down (The Wall Street Journal)
01:00PM	Novartis Ag (NVS) Q3 2024 Earnings Call Transcript (Motley Fool)
11:50AM	Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler (TipRanks)
10:57AM	Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis (GuruFocus.com)
09:34AM	Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down (RTT News)
09:30AM	Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:52AM	Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook (Benzinga)
07:39AM	Novartis Reports Q3 Momentum, But Shares Lose Support (Investor's Business Daily)
07:39AM	Novartis Earnings Show Q3 Momentum, But Shares Lose Support (Investor's Business Daily)
07:09AM	Novartis Lifts Guidance Again After Key Drugs Help Results (The Wall Street Journal)
07:08AM	Stocks to Watch Tuesday: Pfizer, McDonald's Trump Media, Ford (The Wall Street Journal)
06:58AM	Novartis Posts Results Above Estimates, Raises Outlook (Investopedia)
05:54AM	Biogen refreshes its C-suite; Novartis writes down MorphoSys assets (BioPharma Dive)
05:07AM	Novartis: Q3 Earnings Snapshot (Associated Press Finance)
02:00AM	Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance (GlobeNewswire)
Oct-28-24 05:40PM	Monte Rosa Almost Doubles Up 94% On A Massive Deal With Novartis (Investor's Business Daily)
02:26PM	This Biotech Stock Has Doubled Its Value Today Here's Why (Investopedia)
02:10PM	Monte Rosa Stock Doubles Up 127% On A Massive Deal With Novartis (Investor's Business Daily)
08:53AM	Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
08:46AM	Why Is Monte Rosa Therapeutics Stock Surging On Monday? (Benzinga)
07:33AM	Monte Rosa joins with Novartis in molecular glue drug deal (BioPharma Dive)
06:19AM	Novartis Fabhalta shows positive outcomes in C3 glomerulopathy treatment (Clinical Trials Arena)
Oct-26-24 07:50PM	Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial (GlobeNewswire)
Oct-24-24 09:15AM	Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics (Zacks)
08:15AM	3 Absurdly Cheap Stocks That Pay High Dividends (Motley Fool)
01:15AM	Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (GlobeNewswire)
Oct-21-24 09:00AM	Novartis gets positive CHMP opinion for Kisqali in early breast cancer (Pharmaceutical Business Review)
Oct-18-24 01:37PM	European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer (Benzinga)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
06:53AM	Novartis receives positive CHMP opinion for Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer (PR Newswire)
Oct-17-24 08:45AM	1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move (Motley Fool)
Oct-15-24 12:00PM	Novartis (NVS) Upgraded to Buy: Here's Why (Zacks)
07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire)
Oct-14-24 09:45AM	2 Magnificent Dividend Stocks to Buy and Hold Forever (Motley Fool)
Oct-10-24 11:58PM	Analyst Report: Novartis AG (Morningstar Research)
09:50AM	Here's Why Novartis (NVS) is a Strong Momentum Stock (Zacks)
Oct-09-24 04:47PM	LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Streets Strong Buy Rating? (TipRanks)
Oct-05-24 06:30PM	Novartis AG (NVS): Driving Long-Term Growth with Strong Pipeline and Innovative Products (Insider Monkey)
Oct-03-24 08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
Oct-01-24 02:51PM	US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next (Benzinga)
Sep-27-24 09:15AM	Volkswagen, Novartis could surprise in Q3 earnings season, UBS analysts warn (Investing.com)
Sep-26-24 08:40AM	MITEM PHARMA acquires global rights to injectable medicine from Novartis (Pharmaceutical Business Review)
Sep-25-24 01:15PM	Analyst Report: Novartis AG (Morningstar Research)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kowalski Robert William	Officer	Aug 12 '24	Proposed Sale	111.72	6,566	733,572		Aug 12 03:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your FINVIZ experience